Thomas F. Fassbender

ORCID: 0000-0002-1520-6736
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Medical Imaging Techniques and Applications
  • Radiopharmaceutical Chemistry and Applications
  • Advanced Radiotherapy Techniques
  • Urologic and reproductive health conditions
  • AI in cancer detection
  • Pericarditis and Cardiac Tamponade
  • Dementia and Cognitive Impairment Research
  • COVID-19 diagnosis using AI
  • Health, Environment, Cognitive Aging
  • Atomic and Subatomic Physics Research
  • Cancer-related gene regulation

University Medical Center Freiburg
2018-2021

University of Freiburg
2018-2021

Klinik und Poliklinik für Nuklearmedizin
2019-2020

Purpose: To evaluate the performance of radiomic features (RF) derived from PSMA PET for intraprostatic tumor discrimination and non-invasive characterization Gleason score (GS) pelvic lymph node status.Patients methods: Patients with prostate cancer (PCa) who underwent [ 68 Ga]-PSMA-11 PET/CT followed by radical prostatectomy dissection were prospectively enrolled (n=20).Coregistered histopathological gross volume (GTV-Histo) in served as reference.133 RF GTV-Histo manually created...

10.7150/thno.32376 article EN cc-by Theranostics 2019-01-01

Abstract Introduction Primary prostate cancer (PCa) can be visualized on prostate-specific membrane antigen positron emission tomography (PSMA-PET) with high accuracy. However, intraprostatic lesions may missed by visual PSMA-PET interpretation. In this work, we quantified and characterized the which have been image addition, investigated whether PSMA-PET-derived radiomics features (RFs) could detect these lesions. Methodology This study consists of two cohorts primary PCa patients: a...

10.1007/s00259-020-05111-3 article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2020-11-18

Accurate delineation of the intraprostatic gross tumor volume (GTV) is a prerequisite for treatment approaches in patients with primary prostate cancer (PCa). Prostate-specific membrane antigen PET (PSMA PET) may outperform MRI GTV detection. However, visual underlies interobserver heterogeneity and time consuming. The aim this study was to develop convolutional neural network (CNN) automated segmentation (GTV-CNN) PSMA PET. Methods: CNN (3D U-Net) trained on 68Ga-PSMA images 152 from 2...

10.2967/jnumed.120.254623 article EN Journal of Nuclear Medicine 2020-10-30

Abstract Purpose Accurate delineation of intraprostatic gross tumor volume (GTV) is mandatory for successful fusion biopsy guidance and focal therapy planning prostate cancer (PCa). Multiparametric magnetic resonance imaging (mpMRI) the current gold standard GTV delineation; however, prostate-specific membrane antigen positron emission tomography (PSMA-PET) emerging as a promising alternative. This study compares between mpMRI 68 Ga-PSMA-PET in large number patients using validated...

10.1007/s00259-020-04827-6 article EN cc-by European Journal of Nuclear Medicine and Molecular Imaging 2020-04-28

Purpose Accurate contouring of intraprostatic gross tumor volume (GTV) is pivotal for successful delivery focal therapies and biopsy guidance in patients with primary prostate cancer (PCa). Contouring GTVs, using 18-Fluor labeled tracer specific membrane antigen positron emission tomography ([ 18 F]PSMA-1007/PET) has not been examined yet. Patients Methods Ten PCa who underwent [ F]PSMA-1007 PET followed by radical prostatectomy were prospectively enrolled. Coregistered histopathological...

10.3389/fonc.2020.600690 article EN cc-by Frontiers in Oncology 2020-12-07

Comparison studies using histopathology as standard of reference enable a validation the diagnostic performance imaging methods. This study analysed (1) impact different image-histopathology co-registration pathways, (2) applied data analysis method and (3) intraindividually compared multiparametric magnet resonance tomography (mpMRI) prostate specific membrane antigen positron emission (PSMA-PET) by approaches. Ten patients with primary PCa who underwent mpMRI [18F]PSMA-1007 PET/CT followed...

10.1038/s41598-021-85028-5 article EN cc-by Scientific Reports 2021-03-12

We hypothesized that dominant intraprostatic lesions (DILs) could be depictured by multimodal imaging techniques (MRI and/or PSMA PET/CT) in patients with primary prostate cancer (PCa) and investigated possible effects of radiotherapy (RT) dose distribution within the DILs on patients' outcome. One hundred thirty-eight localized visible DIL underwent external beam RT between 2008 2016 an aimed prescription 76 Gy to whole prostate. Seventy-five (54%) additionally received androgen deprivation...

10.1186/s13014-018-1014-1 article EN cc-by Radiation Oncology 2018-04-12

Focal therapies or focally escalated of primary prostate cancer are becoming more and important. This increases the need to identify exact extension intraprostatic tumor possible dominant lesions by imaging techniques. While prostate-specific membrane antigen (PSMA) is already a well-established target for cells, gastrin-releasing peptide receptor (GRPR) seems provide interesting additional information. Histopathology was used examine extent which single combined image information PET scans...

10.1186/s13550-020-00652-y article EN cc-by EJNMMI Research 2020-06-12

Radioligand therapy with [177Lu]PSMA-617 (PSMA-RLT) is a promising therapeutic option for metastatic castration-resistant prostate cancer (mCPRP). This study assessed the prognostic value of early PSA measurements during PSMA-RLT. 27 patients mCRPC scheduled PSMA-RLT were prospectively enrolled serial short-interval PSA-assessment. Change in (∆%PSA) two treatment cycles was correlated biochemical response (BR) and change tumor volume on PET (TV) after 16 weeks (w16), as well overall survival...

10.3390/cancers14010149 article EN Cancers 2021-12-29

A 31-year-old man developed diarrhea, fatigue, and intermittent fever for 2 weeks. The past few days he had experienced increasing dyspnea dry cough. Ambulatory reverse transcriptase-polymerase chain reaction testing was positive SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). Because of elevated D-dimer (1.5 mg/L), a lung scintigraphy (V/Q scan) performed as SPECT/CT. Ventilation SPECT showed reduced ventilation with central nuclide deposition, whereas perfusion inconspicuous,...

10.1097/rlu.0000000000003196 article EN Clinical Nuclear Medicine 2020-06-26

Accurate delineation of the intraprostatic gross tumour volume (GTV) is a prerequisite for treatment approaches in patients with primary prostate cancer (PCa). Prostate-specific membrane antigen positron emission tomography (PSMA-PET) may outperform MRI GTV detection. However, visual underlies interobserver heterogeneity and time consuming. The aim this study was to develop convolutional neural network (CNN) automated segmentation (GTV-CNN) PSMA-PET. Methods: CNN (3D U-Net) trained on...

10.48550/arxiv.2008.03201 preprint EN other-oa arXiv (Cornell University) 2020-01-01

Methoden des Deep-Learnings haben in den letzten Jahren erhebliche Erfolge bei der Lösung unterschiedlicher technischer Probleme erzielt und auch Medizin werden sie zunehmend zur Analyse von (Bild-)daten verwendet. Wir untersuchten, wie gut ein Neuronales Netz basierend auf FDG-PET-Daten Gehirns vorhersagen kann, ob Patient mit geringer kognitiver Einschränkung (engl.: MCI = mild cognitive impairment) Folge eine Alzheimer-Demenz (AD) entwickeln wird.

10.1055/s-0039-1683504 article DE Nuklearmedizin - NuclearMedicine 2019-03-01

Ziel/Aim Fokale bzw. fokal eskalierte Therapieansätze gewinnen auch bei der Therapie des primären Prostatakarzinoms an Bedeutung. Für solche Therapien ist die Kenntnis genauen, lokalen Tumorausdehnung unerlässlich. Bessere Bildgebungstechniken sind dafür Schlüssel. Der Gastrin-releasing peptide receptor und das Prostataspezifische Membranantigen zwei interessante Targets für PET Bildgebung von Prostatazellen. Es wurden Bilddaten Ga-68-RM2-PET/CT (RM2-PET) Untersuchungen mit Histologie...

10.1055/s-0040-1708149 article DE Nuklearmedizin - NuclearMedicine 2020-04-01
Coming Soon ...